Navigation Links
Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors
Date:8/29/2014

BOSTON, Aug. 29, 2014 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostics medical device company based in Boston announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd  was appointed to the company's Board of Directors.

"Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital," said Remis Bistras, President and CEO of Vittamed. "We are extremely delighted to add his clinical, strategic, and entrepreneurial expertise to our Board."

Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen's University Belfast. He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons.  He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds.  

"I am honored to join Vittamed at this exciting time in its history," said Dr. Dagi.  "With the recent CE mark approval for both its products and multiple near-term commercial opportunities, I look forward to helping Vittamed achieve its mission of delivering non-invasive neuromonitoring and diagnostics to patients with unmet medical needs."

He received an AB from Columbia, and an MD and MPH from Johns Hopkins. He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen's University Belfast for contributions to medicine and public service. 

About Vittamed
Vittamed is a Boston-based company with R&D operations in Lithuania. Using ultrasound based technology, it has developed a suite of clinically proven and validated devices.  The Vittamed 205 is a non-invasive Intracranial Pressure (ICP) meter and the Vittamed 505 is a non-invasive Cerebrovascular Perfusion and Autoregulation monitoring device.  Multiple prospective clinical trials with several hundred patients have proven that the Vittamed devices deliver reliable, clinically acceptable, accurate and precise results as compared to today's standard of care using invasive intraventricular and lumbar puncture ICP measurements.  Recently Vittamed received CE mark for its both devices and is preparing for commercialization in the EU as well as 510 (k) filing in the US.

For more information, please visit www.vittamed.com


'/>"/>
SOURCE Vittamed Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
2. Meditope Biosciences Appoints Prominent Scientific Advisory Board
3. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
4. Sanomedics Signs Definitive Agreement for Acquisition of a prominent Texas based Sleep Services company.
5. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
6. Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
7. La Jolla Neurosurgeon Introduces Cutting-Edge Surgery for Scoliosis Patients
8. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
9. Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures
10. Vivex Biomedical and Akron Biotech: Collaborative Venture in Regenerative Medicine
11. Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
(Date:5/25/2016)... 2016 Digital Health Dialog, LLC dba ... the US Patent and Trademark Office of U.S. ... processes for electronic opt-­in and processing of discount ... HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to opt­-in ...
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... Eating Recovery Center, Washington ... a brand new child and adolescent residential treatment center on June 1. The ... more specialized eating disorder treatment and access to life-saving care. , To celebrate, ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical ... at Blackhorse Golf Club in Cypress. With the help of community partners, the event ... empowers, and renews hope for wounded service members and their families through health, wellness, ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon and ... of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International Conference ... 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on stem ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, ... his wonderful accolades and stellar patient reviews, Dr. Batelli continues to be recognized ... Eugene Batelli is a highly trained Podiatric Surgeon who specializes in treating athletes ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... (also knowns as a bunionette) treatment was more than humbled by customer demand over ... one of their SKU's mid sale. Now that Bunion Bootie has completely replenished its ...
Breaking Medicine News(10 mins):